Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27755016 | 0.93 | GPR119 (0.45) | KDM4EPKMGPR119TGFBR1BRD4 | |
| SCHEMBL27755009 | 0.91 | GPR119 (0.47) | KDM4EPKMGPR119CYP3A4CYP2C9 | |
| SCHEMBL27769021 | 0.88 | KDM4E (0.45) | KDM4EPKMGPR119TGFBR1BRD4 | |
| SCHEMBL27769067 | 0.86 | GPR119 (0.42) | KDM4EPKMGPR119CYP3A4CYP2C9 | |
| SCHEMBL27734757 | 0.84 | HTR6 (0.49) | KDM4EPKMGPR119TGFBR1MAPT | |
| SCHEMBL387995 | 0.82 | GPR119 (0.47) | KDM4EPKMGPR119TGFBR1CYP3A4 | |
| SCHEMBL27769026 | 0.82 | PIK3CA (0.44) | KDM4EPKMGPR119TGFBR1BRD4 | |
| SCHEMBL27755184 | 0.80 | GPR119 (0.58) | GPR119TGFBR1CYP3A4 | |
| SCHEMBL27734735 | 0.80 | KDM4E (0.42) | KDM4EPKMGPR119TGFBR1 | |
| SCHEMBL27769006 | 0.80 | PIK3CD (0.45) | KDM4EPKMGPR119TGFBR1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101420941-A | Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, and related combination therapies | ARENA PHARM INC (US) | 2009-04-29 | — | — | CN | disclosed |
| CN-101332303-A | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level | ARENA PHARM INC (US) | 2008-12-31 | — | — | CN | disclosed |